Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat. The event is scheduled for the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 10:00 a.m. ET. A live webcast and replay will be available on the company's investor relations website.

Prestige Consumer Healthcare Inc. completed the acquisition of the OTC Wellness Business for $1.045 billion, funded by a new term loan, expanding its healthcare brand portfolio. For the three months ended June 30, 2026, total revenues increased to $265.7 million, up from $249.5 million in the prior year. However, net income decreased to $29.2 million and diluted EPS fell to $0.61, primarily due to acquisition-related costs and higher interest expense. The company also secured additional financing for another acquisition post-quarter.

Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, with revenue up 6.5% to $265.7 million and organic sales growth of 3.2%, exceeding expectations. The company also announced the completion of the Breathe Right® and LaCorium acquisitions. Consequently, Prestige Consumer Healthcare raised its fiscal 2027 outlook for revenue, Adjusted Diluted EPS, and Adjusted Free Cash Flow, reflecting the positive impact of these strategic acquisitions and robust business performance.

Prestige Brands, Inc., a wholly owned subsidiary of Prestige Consumer Healthcare Inc., has issued $400.0 million in 6.250% senior notes due 2034. The notes are senior unsecured obligations, guaranteed by the parent company and certain subsidiaries, with interest payable semi-annually. The Indenture includes standard covenants restricting certain corporate actions and outlines redemption options for Prestige Brands, including a make-whole premium for early redemption and a 101% repurchase offer in case of a Change of Control.

Prestige Consumer Healthcare Inc. has completed the acquisition of LaCorium Health for approximately $150 million in cash, financed by cash on hand and existing credit facilities. LaCorium Health, an Australian therapeutic skin care leader, is expected to generate approximately $40 million in annual revenue and $12 million in EBITDA post-integration. Additionally, the company priced a private offering of $400 million in 6.25% senior notes due 2034, with proceeds intended to redeem existing 5.125% senior notes due January 2028. Prestige will report its first quarter fiscal 2027 results on August 6, 2026.

Prestige Consumer Healthcare Inc. announced that its wholly-owned subsidiary, Prestige Brands, Inc., plans to offer up to $400 million in new senior notes due 2034 through a private offering. The company intends to use the net proceeds from this offering, combined with cash on hand, to redeem all outstanding $400 million of Prestige Brands' 5.125% Senior Notes due 2028. The redemption of the 2028 notes is contingent upon the successful completion of the new notes offering.

Prestige Consumer Healthcare Inc. announced its 2026 Annual Meeting of Stockholders for August 4, 2026, where shareholders will vote on the election of six directors, an advisory resolution on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. Director Sheila A. Hopkins will retire from the Board, reducing its size to six members. The company also highlighted its Fiscal 2026 performance, reporting $1,089 million in revenue, $4.38 Adjusted Diluted EPS (down 3%), and approximately $246 million in Free Cash Flow, which enabled the fiscal 2027 acquisition of Breathe Right®.

Prestige Consumer Healthcare Inc. announced the completion of its previously announced acquisition of the Breathe Right ® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion. The acquisition, which makes Breathe Right ® the company's largest brand and expands it into a new category, was financed through a combination of available cash and a new $1.045 billion Term Loan Facility. Additionally, the company amended its ABL Credit Agreement, increasing commitments to $225 million and extending its maturity.

Prestige Consumer Healthcare Inc. announced its participation in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference. The virtual event is scheduled for Monday, June 8, 2026, at 9:45 a.m. ET. Investors can access a live webcast and a replay option on the company's investor relations website.

Prestige Consumer Healthcare Inc. is an OTC health and personal care products company operating in North American and International segments. The company has a definitive agreement to acquire the Breathe Right and Dimetapp brands from Foundation Consumer Brands, LLC, anticipated to close in the first half of fiscal 2027. In fiscal 2026, its North American OTC Healthcare segment represented 83.9% of net revenues, while major brands contributed 83.5% of total revenues, with 63.7% from #1 market position brands.